Merck’s and Pfizer’s Bavencio Wins EU Approval for Urothelial Carcinoma

Merck and Pfizer have won European Commission marketing authorization for Bavencio (avelumab) as a first-line maintenance treatment for adults with locally advanced or metastatic urothelial carcinoma who are progression-free after platinum-based chemotherapy.

The approval was supported by positive phase 3 results demonstrating the drug significantly improved survival in patients with advanced or metastatic bladder cancer.

Bavencio received FDA approval last June as a first-line treatment for patients with advanced urothelial carcinoma.